|Dr. Carl Alan Jason Morton Firth||Chairman & CEO||N/A||N/A||1973|
|Mr. Kiran Asarpota||VP of Fin.||N/A||N/A||1979|
|Charlie Hsu||Investor Relations Director||N/A||N/A||N/A|
|Mr. Ben Goodger||Gen. Counsel||N/A||N/A||1963|
|Chi-Chin Wang||IR & Corp. Devel. Director||N/A||N/A||N/A|
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4. Its Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer. It is also conducting a Phase II/III clinical trial of varlitinib for gastric cancer; and testing in a single-arm pivotal clinical trial in biliary tract cancer in China. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL Limited. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.
ASLAN Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.